9903233-6
IPS

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07D 239/91, 401/06, 417/06, 401/14, 405/06, 413/06, A61K 31/505 // C07M 7:00

A1

(11) International Publication Number: **WO 98/38173**

(43) International Publication Date: 3 September 1998 (03.09.98)

(21) International Application Number: PCT/IB98/00150

(22) International Filing Date: 6 February 1998 (06.02.98)

(30) Priority Data:
60/038,905 28 February 1997 (28.02.97) US

(71) Applicant *(for all designated States except US)*: PFIZER PRODUCTS INC. [US/US]; Eastern Point Road, Groton, CT 06340 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: WELCH, Willard, McKowan, Jr. [US/US]; 116 Pequot Avenue, Mystic, CT 06355 (US). DeVRIES, Keith, M. [US/US]; 4 Waterhouse Lane, Chester, CT 06412 (US).

(74) Agents: SPIEGEL, Allen, J. et al.; Pfizer Inc., Patent Dept., 235 East 42nd Street, New York, NY 10017 (US).


(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: ATROPISOMERS OF 3-ARYL-4(3H)-QUINAZOLINONES AND THEIR USE AS AMPA-RECEPTOR ANTAGONISTS

(57) Abstract

Atropisomers of formula (Ia), wherein R^2 is an optionally substituted aryl or heteroaryl, R^5 is alkyl, halo, CF_3, alkoxy or alkylthio, R^6, R^7 and R^8 are hydrogen or halo, and R^3 is hydrogen, halo, CN, NO_2, CF_3, alkyl or alkoxy, are useful as AMPA receptor antagonists, particularly in the treatment of neurodegenerative and CNS-trauma related conditions.



(Ia)